Endpoints News 9. März 2026 GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
Endpoints News 7. März 2026 UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more
Endpoints News 6. März 2026 Pfizer gets obesity drug approval in China shortly after buying local rights
Endpoints News 6. März 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 5. März 2026 Helus Pharma's stock slides after psychedelic drug data face questions over dosing